CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

Most recent changes to this medium descriptor document:
- Deleted codes in this document appear with a strikethrough.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

The following code was accepted at the March 2020 CPT Editorial Panel meeting for the 2021 CPT production cycle. This code is effective immediately on March 13, 2020.

<table>
<thead>
<tr>
<th>Code</th>
<th>Medium Code Descriptor</th>
<th>Released to AMA website</th>
<th>Effective</th>
<th>Publication</th>
</tr>
</thead>
</table>

The following codes were accepted and revised at the April 2020 CPT Editorial Panel meeting for the 2021 CPT production cycle. These codes are effective immediately on April 10, 2020.

<table>
<thead>
<tr>
<th>Code</th>
<th>Medium Code Descriptor</th>
<th>Released to AMA website</th>
<th>Effective</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲86318</td>
<td>IMMUNOASSAY INFECTION AGT ANTIBODY QUAL/SEMIOQUAL 1ST STEP METH</td>
<td>April 10, 2020</td>
<td>April 10, 2020</td>
<td>CPT® 2021</td>
</tr>
<tr>
<td>#●86328</td>
<td>IA INFECTION AGT ANTIBODY SARS-COV-2 COVID-19</td>
<td>April 10, 2020</td>
<td>April 10, 2020</td>
<td>CPT® 2021</td>
</tr>
<tr>
<td>●86769</td>
<td>ANTIB SEVERE AQI RESPIR SYND SARS-COV-2 COVID-19</td>
<td>April 10, 2020</td>
<td>April 10, 2020</td>
<td>CPT® 2021</td>
</tr>
</tbody>
</table>

The following code was accepted by the Executive Committee of the CPT Editorial Panel. This code is effective immediately on June 25, 2020.
CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Start Date</th>
<th>End Date</th>
<th>CPT® Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>●87426</td>
<td>IAAD IA SEVERE AQT RESPIR SYND CORONAVIRUS</td>
<td>June 25, 2020</td>
<td>June 25, 2020</td>
<td>CPT® 2022</td>
</tr>
</tbody>
</table>

The following codes were accepted by the CPT Editorial Panel. These codes are effective immediately on August 10, 2020.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Start Date</th>
<th>End Date</th>
<th>CPT® Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>#●86408</td>
<td>NEUTRALIZING ANTIBODY SARS-COV-2 SCREEN</td>
<td>August 10, 2020</td>
<td>August 10, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>#●86409</td>
<td>NEUTRALIZING ANTIBODY SARS-COV-2 TITER</td>
<td>August 10, 2020</td>
<td>August 10, 2020</td>
<td>CPT® 2022</td>
</tr>
</tbody>
</table>

The following codes were accepted by the CPT Editorial Panel. These codes are effective immediately on September 8, 2020.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Start Date</th>
<th>End Date</th>
<th>CPT® Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>#●86413</td>
<td>SEV AQT RESPIR SYND CORONAVIRUS 2 ANTIBODY QUAN</td>
<td>September 8, 2020</td>
<td>September 8, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>●99072</td>
<td>ADDL SUPL MATRL&amp;STAF TM DRG PHE RES-TR NFCT DS</td>
<td>September 8, 2020</td>
<td>September 8, 2020</td>
<td>CPT® 2022</td>
</tr>
</tbody>
</table>

The following codes were accepted, revised, and deleted by the CPT Editorial Panel. These codes are effective immediately on October 6, 2020.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Start Date</th>
<th>End Date</th>
<th>CPT® Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲87301</td>
<td>IAAD IA ADENOVIRUS ENTERIC TYP 40/41</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87305</td>
<td>IAAD IA QUAL/SEMIQUAN MULTIPLE STEP ASPERGILLUS</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
</tbody>
</table>
CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Date</th>
<th>Date</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲87320</td>
<td>IAAD IA CHLAMYDIA TRACHOMATIS</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87324</td>
<td>IAAD IA CLOSTRIDUM DIFFICILE TOXIN</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87327</td>
<td>IAAD IA CRYPTOCOCCUS NEOFORMANS</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87328</td>
<td>IAAD IA CRYPTOSPORIDIUM</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87329</td>
<td>IAAD IA GIARDIA</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87332</td>
<td>IAAD IA CYTOMEGALOVIRUS</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87335</td>
<td>IAAD IA ESCHERICHIA COLI 0157</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87336</td>
<td>IAAD IA ENTAMOEBA HISTOLYTICA DISPAR GRP</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87337</td>
<td>IAAD IA ENTAMOEBA HISTOLYTICA GRP</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
</tbody>
</table>
## CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Date</th>
<th>Date</th>
<th>CPT® Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲87338</td>
<td>IAAD IA HPYLORI STOOL</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>▲87339</td>
<td>IAAD IA HPYLORI</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>▲87340</td>
<td>IAAD IA HEPATITIS B SURFACE ANTIGEN</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>▲87341</td>
<td>IAAD IA HEPATITIS B SURFACE AG NEUTRALIZATION</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>▲87350</td>
<td>IAAD IA HEPATITIS BE ANTIGEN</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>▲87380</td>
<td>IAAD IA HEPATITIS DELTA ANTIGEN</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>▲87385</td>
<td>IAAD IA HISTOPLASM CAPSULATUM</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>▲87389</td>
<td>IAAD IA HIV-1 AG W/HIV-1 &amp; HIV-2 ANTBDY SINGLE</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>▲87390</td>
<td>IAAD IA HIV-1</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>2022</td>
</tr>
</tbody>
</table>
CPT® Category I and Proprietary Laboratory Analyses (PLA) 
Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Date</th>
<th>Date</th>
<th>Version</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲87391</td>
<td>IAAD IA HIV-2</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87400</td>
<td>IAAD IA INFLUENZA A/B EACH</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87420</td>
<td>IAAD IA RESPIRATORY SYNCYTIAL VIRUS</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87425</td>
<td>IAAD IA ROTAVIRUS</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲▲87426</td>
<td>IAAD IA SEVERE AQI RESPIR SYND CORONAVIRUS</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87427</td>
<td>IAAD IA SHIGA-LIKE TOXIN</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87430</td>
<td>IAAD IA STREPTOCOCCUS GROUP A</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>▲87449</td>
<td>IAAD IA MULT STEPP METHOD NOS NOT OTHERWISE SPECIFIED EACH ORGANISM</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>87450</td>
<td>IAAD IA SINGLE STEPP METHOD NOS EA ORGANISM</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Date</td>
<td>Date</td>
<td>Year</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------</td>
<td>------------</td>
<td>-------</td>
</tr>
<tr>
<td>87451</td>
<td>IAAD IA POLYV MLT ORGANISMS EA POLYV ANTISERUM</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>87636</td>
<td>IADNA SARS-CoV2&amp; INF A&amp;B MULT AMPLIFIED PROBE TQ</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>87637</td>
<td>IADNA SARS-CoV2 &amp; INF A&amp;B &amp; RSV MULT AMP PROBE TQ</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>87802</td>
<td>IAADIADOO STREPTOCOCCUS GROUP B</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>87803</td>
<td>IAADIADOO CLOSTRIDIUM DIFFICILE TOXIN A</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>87806</td>
<td>IAADIADOO HIV1 ANTIGEN W/HIV1 &amp; HIV2 ANTIBODIES</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>87804</td>
<td>IAADIADOO INFLUENZA</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>87807</td>
<td>IAADIADOO RESPIRATORY SYNCTIAL VIRUS</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>87114</td>
<td>IAADIADOO SEVERE AQRT RESPIR SYND CORONAVIRUS</td>
<td>October 6, 2020</td>
<td>October 6, 2020</td>
<td>CPT® 2022</td>
</tr>
</tbody>
</table>
CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Effective Date</th>
<th>CPT®</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>▲87808</td>
<td>IAADIADOO TRICHOMONAS VAGINALIS</td>
<td>October 6, 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲87809</td>
<td>INFECTIOUS AGENT IMMUNOASSAY OPTICAL</td>
<td>October 6, 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IAADIADOO ADENOVIRUS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲87810</td>
<td>IAADIADOO CHLAMYDIA TRACHOMATIS</td>
<td>October 6, 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲87850</td>
<td>IAADIADOO NEISSERIA GONORROEAE</td>
<td>October 6, 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲87880</td>
<td>IAADIADOO STREPTOCoccus GROUP A</td>
<td>October 6, 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>▲87899</td>
<td>IAADIADOO NOT OTHERWISE SPECIFIED</td>
<td>October 6, 2020</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The following codes were accepted by the CPT Editorial Panel. *Note that resequenced code 87428 will follow code 87426 and is effective immediately on November 10, 2020. Codes 0001A, 0002A, and 91300 are effective December 11, 2020. Codes 0011A, 0012A, and 91301 are effective December 18, 2020. Codes 0031A, 91303 are effective February 27, 2021. Codes 0003A, 0013A are effective August 12, 2021. Codes 0004A, 0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0054A, 91302, 91304, 91305, and 91306 will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Effective Date</th>
<th>CPT®</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>#●87428</td>
<td>IAAD IA SARSCOV &amp; INFLUENZA VIRUS TYPES A&amp;B</td>
<td>November 10, 2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>●0001A</td>
<td>IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON 1ST DOSE</td>
<td>November 10, 2020</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CPT © Copyright 2021 American Medical Association. All rights reserved. AMA and CPT are registered trademarks of the American Medical Association. Updated September 3, 2021
### CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

<table>
<thead>
<tr>
<th>Code</th>
<th>Procedure Description</th>
<th>Start Date</th>
<th>End Date</th>
<th>CPT® Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>0002A</td>
<td>IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON 2ND DOSE</td>
<td>November 10, 2020</td>
<td>December 11, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>0003A</td>
<td>IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON 3RD DOSE</td>
<td>July 30, 2021</td>
<td>August 12, 2021</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>0004A</td>
<td>IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON BST DOSE</td>
<td>September 3, 2021</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>0051A</td>
<td>IMM ADMN SARSCOV2 30MCG/0.3ML TRIS-SUCROSE 1ST</td>
<td>September 3, 2021</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>0052A</td>
<td>IMM ADMN SARSCOV2 30MCG/0.3ML TRIS-SUCROSE 2ND</td>
<td>September 3, 2021</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2023</td>
</tr>
</tbody>
</table>
# CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Date</th>
<th>Effective Upon Receiving</th>
<th>CPT® Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>#0053A</td>
<td>IMM ADMN SARSCOV2 30MCG/0.3ML TRIS-SUCROSE 3RD</td>
<td>September 3, 2021</td>
<td>Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>#0054A</td>
<td>IMM ADMN SARSCOV2 30MCG/0.3ML TRIS-SUCROSE BST</td>
<td>September 3, 2021</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>0011A</td>
<td>IMM ADMN SARSCOV2 100 MCG/0.5 ML 1ST DOSE</td>
<td>November 10, 2020</td>
<td>December 18, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>0012A</td>
<td>IMM ADMN SARSCOV2 100 MCG/0.5 ML 2ND DOSE</td>
<td>November 10, 2020</td>
<td>December 18, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>0013A</td>
<td>IMM ADMN SARSCOV2 100 MCG/0.5 ML 3RD DOSE</td>
<td>August 16, 2021</td>
<td>August 12, 2021</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>#0064A</td>
<td>IMM ADMN SARSCOV2 50 MCG/0.25 ML BOOSTER DOSE</td>
<td>September 3, 2021</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td>CPT® 2023</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Effective Date</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------------------</td>
<td>-------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>0021A</td>
<td>IMM ADMN SARCSCOV2 5X10^10 VP/0.5 ML 1ST DOSE</td>
<td>December 17, 2020</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td></td>
</tr>
<tr>
<td>0022A</td>
<td>IMM ADMN SARCSCOV2 5X10^10 VP/0.5 ML 2ND DOSE</td>
<td>December 17, 2020</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td></td>
</tr>
<tr>
<td>0031A</td>
<td>IMM ADMN SARCSCOV2 AD26 5X10^10 VP/0.5 ML 1 DOSE</td>
<td>January 19, 2021</td>
<td>February 27, 2021</td>
<td></td>
</tr>
<tr>
<td>0041A</td>
<td>IMM ADMN SARCSCOV2 5 MCG/0.5 ML 1ST DOSE</td>
<td>May 4, 2021</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td></td>
</tr>
<tr>
<td>0042A</td>
<td>IMM ADMN SARCSCOV2 5 MCG/0.5 ML 2ND DOSE</td>
<td>May 4, 2021</td>
<td>Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</td>
<td></td>
</tr>
<tr>
<td>91300</td>
<td>SARCSCOV2 VACCINE DIL RECON 30 MCG/0.3 ML IM USE</td>
<td>November 10, 2020</td>
<td>December 11, 2020</td>
<td></td>
</tr>
</tbody>
</table>
CPT® Category I and Proprietary Laboratory Analyses (PLA) Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Effective Upon Receiving Emergency Use Authorization or Approval from the Food and Drug Administration</th>
<th>CPT® Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>91305</td>
<td>SARS-CoV2 VACCINE 30MCG/0.3ML TRIS-SUCROSE IM USE</td>
<td>September 3, 2021</td>
<td>2023</td>
</tr>
<tr>
<td>91301</td>
<td>SARS-CoV2 VACCINE 100 MCG/0.5 ML IM USE</td>
<td>November 10, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>91306</td>
<td>SARS-CoV2 VACCINE 50 MCG/0.25 ML IM USE</td>
<td>September 3, 2021</td>
<td>2023</td>
</tr>
<tr>
<td>91302</td>
<td>SARS-CoV2 VACCINE CHADOX1 5x10^{10} VP/0.5ML IM USE</td>
<td>December 17, 2020</td>
<td>2022</td>
</tr>
<tr>
<td>91303</td>
<td>SARS-CoV2 VACCINE AD26 5x10^{10} VP/0.5ML IM USE</td>
<td>January 19, 2021</td>
<td>2022</td>
</tr>
<tr>
<td>91304</td>
<td>SARS-CoV2 VACC SAPONIN-BSD ADJT 5MCG/0.5ML IM USE</td>
<td>May 4, 2021</td>
<td>2022</td>
</tr>
</tbody>
</table>
CPT® Category I and Proprietary Laboratory Analyses (PLA)
Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

The following code was accepted by the Executive Committee of the CPT Editorial Panel for the 2021 CPT production cycle. This code is effective immediately on May 20, 2020.

<table>
<thead>
<tr>
<th>Proprietary Name and Clinical Laboratory or Manufacturer</th>
<th>Code</th>
<th>Medium Code Descriptor</th>
<th>Released to AMA Website</th>
<th>Effective Date</th>
<th>Publication</th>
</tr>
</thead>
</table>

The following codes were accepted by the Executive Committee of the CPT Editorial Panel. These codes are effective immediately on June 25, 2020.

<table>
<thead>
<tr>
<th>Proprietary Name and Clinical Laboratory or Manufacturer</th>
<th>Code</th>
<th>Medium Code Descriptor</th>
<th>Released to AMA Website</th>
<th>Effective Date</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 Antibody Test, Mt Sinai, Mount Sinai Laboratory</td>
<td>●0224U</td>
<td>ANTIB SEV AQT RESPIR SYND CORONAVIRUS 2 TITER(S)</td>
<td>June 25, 2020</td>
<td>June 25, 2020</td>
<td>CPT® 2022</td>
</tr>
</tbody>
</table>

The following codes were accepted by the CPT Editorial Panel. These codes are effective immediately on August 10, 2020.

<table>
<thead>
<tr>
<th>Proprietary Name and Clinical Laboratory or Manufacturer</th>
<th>Code</th>
<th>Medium Code Descriptor</th>
<th>Released to AMA Website</th>
<th>Effective Date</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>ePlex® Respiratory Pathogen Panel 2, GenMark Dx, GenMark Diagnostics, Inc</td>
<td>●0225U</td>
<td>NFCT DS DNA&amp;RNA 21 TARGETS SARS-COV-2 AMP PROBE</td>
<td>August 10, 2020</td>
<td>August 10, 2020</td>
<td>CPT® 2022</td>
</tr>
<tr>
<td>Tru-Immune™, Ethos Laboratories, GenScript® USA Inc</td>
<td>●0226U</td>
<td>SUROGAT VIR NEUTRLJZ TST SARSCOV2 ELISA PLSM SRM</td>
<td>August 10, 2020</td>
<td>August 10, 2020</td>
<td>CPT® 2022</td>
</tr>
</tbody>
</table>

The following codes were accepted by the CPT Editorial Panel. These codes are effective immediately on October 6, 2020.
CPT® Category I and Proprietary Laboratory Analyses (PLA)
Codes for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])

| Xpert® Xpress SARS-CoV-2/Flu/RSV (SARS-CoV-2 & Flu targets only), Cepheid | NFCT DS RNA 3 TARGETS UPPER RESPIRATORY SPECIMEN | October 6, 2020 | October 6, 2020 | CPT® 2022 |
| Xpert® Xpress SARS-CoV-2/Flu/RSV (all targets), Cepheid | NFCT DS RNA 4 TARGETS UPPER RESPIRATORY SPECIMEN | October 6, 2020 | October 6, 2020 | CPT® 2022 |